3rd Quarter Results
|
Issued: Wednesday, 22nd October 2008, London, U.K. Results announcement for the third quarter 2008 GSK delivers Q3 business performance* |
|
Business performance results* |
||||||
|
|
|
|
9 months |
|
||
|
|
£m |
CER% |
£% |
£m |
CER% |
£% |
|
Turnover |
5,882 |
(3) |
7 |
17,442 |
(2) |
4 |
|
Earnings per share |
25.2p |
(9) |
6 |
78.0p |
(5) |
4 |
|
Statutory results (including restructuring charges) |
||||||
|
|
|
|
9 months 2008 |
|
||
|
|
£m |
CER% |
£% |
£m |
CER% |
£% |
|
Turnover |
5,882 |
(3) |
7 |
17,442 |
(2) |
4 |
|
Earnings per share |
20.1p |
(30) |
(15) |
69.2p |
(16) |
(7) |
|
The full results are presented under 'Income Statement' on pages 8 and 16. |
||||||
|
Q3 business performance summary |
|
|
• |
EPS down 9% at constant exchange rates, up 6% in sterling terms benefiting from currency movements |
|
• |
Continued sales growth in vaccines, emerging markets and consumer healthcare helped offset impact of generic competition to US pharmaceuticals |
|
• |
Portfolio renewal continues with 10 product launches so far in 2008, including Rotarix (USA), Treximet (USA) and Tyverb (EU) |
|
• |
Strong R&D productivity evident with a sustained level of around 30 assets in late-stage development |
|
• |
Early progress in strategy to globalise and diversify business with 'bolt-on' acquisitions in emerging markets and consumer healthcare |
|
• |
Q3 dividend increased 8% to 14p. |
|
* |
Business performance, which is a supplemental measure, is the primary performance measure used by management and is presented after excluding restructuring charges relating to the current operational excellence programme, which commenced in October 2007, and significant acquisitions. Management believes that exclusion of these items provides a better reflection of the way in which the business is managed and gives a more useful indication of the underlying performance of the Group. In order to illustrate underlying performance, it is the Group's practice to discuss its results in terms of constant exchange rate (CER) growth. All commentaries are presented in terms of CER growth and compare 2008 business performance results with 2007 statutory results, unless otherwise stated. |
|
Chief Executive Officer's Review |
|
We are managing a considerable transition to our product portfolio this year as several mature pharmaceutical brands encounter generic competition in the USA. In the short-term, this is having a significant impact on pharmaceutical sales, although we continue to see good growth from other areas of the pharmaceuticals portfolio, including a recent improvement in prescription volumes for Advair in the United States. Also helping offset the generic impact has been growth in other parts of our business, such as vaccines, emerging markets and consumer healthcare. This diversification in sales is an inherent strength for GSK and one we are actively nurturing, through delivery and investment in our new strategic priorities. Ultimately, we are aiming to create a more balanced healthcare business with a lower overall risk profile. Grow a diversified global business In Pharmaceuticals, we are making good progress to renew our product line, with 10 product launches so far this year in critical growth areas, such as oncology, and in existing franchises. In the future, we want our portfolio to be more balanced with a lower concentration of sales in any one or two products. Clearly, our agenda must then be to maximise the value of this broader portfolio and we are therefore deliberately taking a more global approach to commercialisation than ever before. The success of Advair in Japan is a good example of driving growth outside our more traditional markets. Advair is at the vanguard of multiple future product opportunities in Japan, with the next product launch expected to be Lamictal, following its approval last week. Overall, we have the potential for more than 40 launches over the next 5 years in this market. In emerging markets, we are starting to make some early progress in building a more tailored portfolio for patients and consumers. We have now formalised our trading agreement with Aspen Pharmaceuticals and have so far identified around 60 assets for prospective commercialisation. We also recently acquired a broad range of pharmaceutical brands from BMS in Egypt. This is a fast growing market and we are now the market leader. Importantly, this acquisition also provides us with the opportunity to grow incremental sales in other markets in the Middle East and North Africa, through export of these products. The dynamics of emerging markets are wholly different to traditional western pharmaceutical markets as there is less distinction between pharmaceutical, over-the-counter and retail market structures. Our capability to supply products and operate across this spectrum is, I believe, a competitive advantage for GSK. On this basis, we are determined to globalise further our Consumer Healthcare business. In September, for example, we introduced Sensodyne - the fastest growing global toothpaste brand - into the Chinese market, our first major consumer product to launch there for a decade. We also see multiple opportunities to build our consumer business through the switch of prescription products and the acquisition of new brands, which can complement and drive the growth of our key franchises. Our recent acquisition of Biotene, a dynamic oral healthcare brand, is evidence of this. |
|
Moving forward, it is clear that we will need to monitor closely the impact that changes in the global economy will have on consumer demand for products. To date, we have seen only modest impact on GSK's consumer products in certain territories. The strength of our diversified business model is that it helps to mitigate any potential impact on GSK as our multiple franchises operate in very different economic cycles. In Vaccines, our sales continue to be dynamic with growth powered by a broad range of brands. We continue to expand this business and this quarter launched two new vaccines in the USA, Rotarix and Kinrix. The potential of this business is significant, given our pipeline; the opportunity for global expansion, and payer needs that are increasingly directed towards preventative healthcare. At the same time, we must compete effectively for what are often binary tender orders and supply agreements. This may produce some volatility in the vaccines sales line as this business grows. Regarding recent tenders we have made good progress, in particular with Cervarix, which has been successful in approximately 60% of competitive tenders, notably in the UK for the largest vaccination programme against HPV in Europe. Deliver more products of value In R&D, we are continuing to make the changes necessary to deliver our pipeline going forward. We have seen a step-change in the number of launches for GSK, and importantly we are replenishing these with new phase III entries. At present, we are maintaining a level of around 30 assets in late-stage development and our strategies in R&D are focused on sustaining this type of productivity. Moreover, GSK continues to deliver innovative products with 6 novel medicines and vaccines either launched or filed in 2008. In fact, around 75% of assets in our pipeline are entirely new compounds or vaccines. By any standard, this is a strong bias towards innovation and demonstrates the value GSK can bring to patients and to payers. We have seen good progress in our late-stage biopharmaceutical portfolio this quarter. New data for ofatumumab, a treatment for patients with chronic lymphocytic leukaemia, will be used to support a licence application planned for the end of the year. Our first in-house developed biopharmaceutical product, Bosatria, was filed for approval in Europe this quarter. We hope this will be a valuable new treatment for patients with the rare, but potentially fatal disease, hypereosinophilic syndrome. Finally, otelixizumab, a new potential treatment for Type I diabetes, entered phase III development in August. Data on several other important assets this quarter further highlighted the potential of GSK's pipeline. New data for cancer treatments, Armala and Tykerb, demonstrated positive effects against several tumour types with high, unmet medical need. In addition, we presented results from a clinical imaging study of darapladib. These data support our belief that Lp-PLA2 inhibition may be an important therapeutic target and we plan to begin phase III clinical studies shortly. When I outlined our new strategic priorities last quarter, I said that GSK has a very clear ambition to realise value in R&D through better allocation of capital. Here, we have made progress through reshaping our R&D organisation and the introduction of new initiatives such as our Drug Discovery Investment Board. This Board has now reviewed 75% of our 3-year investment plans for drug discovery, with the remainder expected by year-end. |
|
We are also seeking to improve productivity and value through externalisation of R&D. This enables us to capture scientific diversity and balance expenditure with risk. We believe new alliances formed this quarter with Cellzome and the Harvard Stem Cell Institute will provide competitive advantage in researching areas such as inflammatory disease, neuroscience and oncology. With all its option-based collaborations, GSK now has access to products and pipelines of 16 companies, bringing further significant breadth and scale to our R&D activities. Combining this capacity with our own organic efforts provides us opportunities for complementary and synergistic research. Staying with this theme, Sirtris, our recent R&D acquisition is now effectively integrated into our discovery organisation. Like Domantis, it will continue to operate as an independent unit, but we have also established numerous research collaborations in the field of sirtuins across GSK, including in our new R&D China organisation. |
|
Simplify GSK's operating model Activities to improve our overall efficiency and create a new operating model for our business are well underway. Our current operational excellence programme is progressing well and we are on track to realise annual savings of at least £350 million in 2008 and £700 million by 2010. We have also commenced a series of reviews to simplify further our business, in particular, with attention to our above-country support infrastructure. Financial strategy We continue to benefit from strong cash generation with net cash inflow from operating activities of over £5 billion, up 6% in sterling terms in the first nine months of this year. Our financial strategy is focused on maintaining an efficient balance sheet, retaining flexibility to invest in our strategic priorities and increasing returns to our shareholders through our progressive dividend policy. This quarter's dividend increased by 8% to 14 pence and we have completed share repurchases of £3.3 billion in the 9 months to 30th September 2008. We expect to have completed around £4 billion of repurchases by the year-end, subject to market conditions. With the recent changes in financial markets we now expect more investment opportunities to arise that will allow us to invest in support of our strategic priorities. To ensure we have sufficient flexibility to take advantage of these opportunities we do not currently expect to make significant share repurchases in 2009. Investment opportunities will continue to be assessed against strict financial criteria. Outlook In summary then, our performance is in line with our expectations and I am pleased with how we have so far responded to what is undoubtedly a challenging year for GSK. Nevertheless, we remain focused on improving our short-term performance. We have also, I believe, started to take some initial steps in the right direction to deliver our strategic agenda to improve long-term sales growth and reduce risk for the company. Andrew Witty Chief Executive Officer |
|
Trading Update |
|
|
|
Turnover and key product movements impacting turnover growth for the quarter Total pharmaceutical turnover for the quarter declined 4% to £4.9 billion, with US turnover down 13% to £2.1 billion, impacted by generic competition to mature brands. In Europe, sales grew 6% to £1.6 billion, emerging markets sales grew 9% to £581 million and Asia Pacific/Japan sales grew 5% to £464 million. Seretide/Advair sales were up 7% to £982 million for the quarter, with sales up 5% in the USA to £515 million and in Japan sales more than doubled to £25 million. Sales growth was also driven by Valtrex, up 21% to £303 million and Lovaza, with US sales of £75 million. |
|
Sales of Avandia products were £191 million, a decline of 23% compared with 2007. There continues to be controversy surrounding the appropriate use of Avandia and consequently the sales outlook for the product remains negative. Lamictal sales declined 59% to £136 million following introduction of generic competition in the US market in July. Sales of Wellbutrin (down 67% to £53 million) and Coreg IR (down 93% to £9 million) also declined due to generic competition in the US market. Vaccines sales grew 12% to £730 million, with hepatitis vaccines up 11% to £174 million, Infanrix/Pediarix up 9% to £168 million and Fluarix/FluLaval up 11% to £144 million. In the USA, this quarter's performance reflected a difficult comparison to particularly strong sales growth in Q3 2007. Cervarix generated £43 million of sales for the quarter. |
|
Consumer Healthcare sales grew 3% to £994 million during the quarter, compared with 16% growth in Q3 2007, which benefited from launch-stocking of alli. Excluding sales of alli, Consumer Healthcare sales grew 5% this quarter. Sales of oral care brands, Aquafresh and Sensodyne, grew 5% and 8% respectively during the quarter, contributing sales of £206 million. Sales of Panadol grew 9% to £82 million, whilst sales of Tums declined 17% to £21 million. Sales of Horlicks grew 10% to £53 million and sales of Lucozade grew 2% to £100 million, principally due to a poor summer in the UK. |
|
Operating profit and earnings per share commentary Business performance Business performance operating profit for Q3 2008 was £1,979 million, a 10% decline in CER terms. This was greater than the turnover decline of 3% in CER terms, primarily due to higher cost of sales as a percentage of turnover. Cost of sales increased to 24.8% of turnover (Q3 2007: 22.5%), principally reflecting the anticipated generic competition to higher margin products in the USA. SG&A costs as a percentage of turnover fell 1.2 percentage points to 28.3% compared with Q3 2007, reflecting the benefits of the current operational excellence programme and other ongoing cost control. R&D expenditure at 14.2% of turnover was broadly unchanged from last year. Pharmaceuticals R&D expenditure in the quarter was 16.4% (Q3 2007: 16.1%) of pharmaceutical turnover. In the quarter, gains from assets disposals were £21 million (Q3 2007: £22 million), costs for legal matters were £58 million (Q3 2007: £64 million), fair value movements on financial instruments, principally the Quest collar which was closed out in the quarter, resulted in a charge of £37 million (Q3 2007: £32 million) and charges related to previous restructuring programmes were £7 million (Q3 2007: £13 million). The impact of these items on business performance operating profit was broadly neutral, compared with Q3 2007. |
|
Business performance EPS of 25.2p decreased 9% in CER terms (a 6% increase in sterling terms) compared with Q3 2007. The favourable currency impact of 15 percentage points reflected a weakening of sterling against most major currencies. Statutory performance Statutory operating profit for Q3 2008 was £1,657 million, down 13% in sterling terms and down 26% CER compared with Q3 2007. This included £322 million of restructuring charges related to the current operational excellence programme; £130 million was charged to cost of sales, £157 million to SG&A and £35 million to R&D. There were no such charges in Q3 2007. Statutory performance EPS of 20.1p decreased 30% in CER terms (15% in sterling terms) compared with Q3 2007. |
|
Cash flow Net cash inflow from operating activities in Q3 2008 was £1,893 million, up 3% in sterling terms. For the nine months net cash inflow from operating activities was £5,067 million, a 6% increase in sterling terms over the previous year. This was used to fund net interest payable of £55 million, capital expenditure on property, plant and equipment and intangible assets of £1,284 million, and acquisitions of £324 million. In addition, dividends paid to shareholders totalled £2,250 million (up 6% compared with 2007) and share repurchases amounted to £3,324 million. |
|
Net debt Net debt increased by £2.6 billion during the nine month period to £8.6 billion at 30th September 2008, comprising gross debt of £14.2 billion and cash and liquid investments of £5.6 billion. |
|
The Group is well placed financially having completed its debt financing programme earlier in the year. At 30th September 2008, GSK had short-term borrowings (including overdrafts) repayable within 12 months of only £1.4 billion with a further £0.6 billion repayable in the subsequent 12-month period. |
|
Dividends The Board has declared a third interim dividend of 14 pence per share (Q3 2007: 13p). The equivalent interim dividend receivable by ADR holders is 47.4796 cents per ADS based on an exchange rate of £1/$1.6957. The ex-dividend date will be 29th October 2008, with a record date of 31st October 2008 and a payment date of 8th January 2009. Currency impact If exchange rates were to hold at the average Q3 2008 levels for the rest of the year, the positive currency impact on business performance EPS growth for the full year would be around 10 percentage points. |
|
2008 earnings guidance GSK continues to expect a mid-single digit percentage decline in business performance EPS at constant exchange rates. |
|
|
|
GlaxoSmithKline (GSK) together with its subsidiary undertakings, the 'Group' - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GlaxoSmithKline's website www.gsk.com gives additional information on the Group. Information made available on the website does not constitute part of this document. |
|
Enquiries: |
UK Media |
Philip Thomson Claire Brough Alice Hunt Gwenan White |
(020) 8047 5502 (020) 8047 5502 (020) 8047 5502 (020) 8047 5502 |
|
|
|
|
|
|
|
US Media |
Nancy Pekarek Sarah Alspach Mary Anne Rhyne |
(919) 483 2839 (215) 751 7709 (919) 483 2839 |
|
|
|
|
|
|
|
European Analyst / Investor |
David Mawdsley Sally Ferguson Gary Davies |
(020) 8047 5564 (020) 8047 5543 (020) 8047 5503 |
|
|
|
|
|
|
|
US Analyst / Investor |
Tom Curry |
(215) 751 5419 |
|
|
|||
|
Brand names Brand names appearing in italics throughout this document are trademarks of GSK or associated companies with the exception of Levitra, a trademark of Bayer, Bonviva/Boniva, a trademark of Roche, Entereg, a trademark of Adolor Corporation in the USA and Vesicare, a trademark of Astellas Pharmaceuticals in many countries and of Yamanouchi Pharmaceuticals in certain countries, all of which are used under licence by the Group. Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007. |
|
|
|
GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom Registered in England and Wales. Registered number: 3888792 |
|
Income statement |
|
Three months ended 30th September 2008 |
|
|
Business |
Growth |
Restructuring |
|
|
|
|
£m |
CER% |
£m |
£m |
£m |
|
|
------ |
------ |
------ |
------ |
------ |
|
Turnover: |
|
|
|
|
|
|
Pharmaceuticals |
4,888 |
(4) |
|
4,888 |
4,591 |
|
Consumer Healthcare |
994 |
3 |
|
994 |
885 |
|
|
------ |
|
|
------ |
------ |
|
TURNOVER |
5,882 |
(3) |
|
5,882 |
5,476 |
|
|
|
|
|
|
|
|
Cost of sales |
(1,460) |
10 |
(130) |
(1,590) |
(1,232) |
|
|
------ |
|
------ |
------ |
------ |
|
Gross profit |
4,422 |
(6) |
(130) |
4,292 |
4,244 |
|
|
|
|
|
|
|
|
Selling, general and administration |
(1,662) |
(5) |
(157) |
(1,819) |
(1,617) |
|
Research and development |
(834) |
2 |
(35) |
(869) |
(769) |
|
Other operating income |
53 |
|
|
53 |
52 |
|
|
------ |
|
------ |
------ |
------ |
|
|
|
|
|
|
|
|
Operating profit: |
|
|
|
|
|
|
Pharmaceuticals |
1,755 |
(12) |
(311) |
1,444 |
1,719 |
|
Consumer Healthcare |
224 |
3 |
(11) |
213 |
191 |
|
|
------ |
|
------ |
------ |
------ |
|
OPERATING PROFIT |
1,979 |
(10) |
(322) |
1,657 |
1,910 |
|
|
|
|
|
|
|
|
Finance income |
98 |
|
|
98 |
75 |
|
Finance expense |
(218) |
|
|
(218) |
(117) |
|
Share of after tax profits of associates |
16 |
|
|
16 |
14 |
|
|
------ |
|
------ |
------ |
------ |
|
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION |
1,875 |
(14) |
(322) |
1,553 |
1,882 |
|
|
|
|
|
|
|
|
Taxation |
(559) |
|
62 |
(497) |
(536) |
|
Tax rate % |
29.8% |
|
|
32.0% |
28.5% |
|
|
------ |
|
------ |
------ |
------ |
|
PROFIT AFTER TAXATION FOR THE PERIOD |
1,316 |
(16) |
(260) |
1,056 |
1,346 |
|
|
------ |
|
------ |
------ |
------ |
|
|
|
|
|
|
|
|
Profit attributable to minority interests |
29 |
|
|
29 |
36 |
|
Profit attributable to shareholders |
1,287 |
|
(260) |
1,027 |
1,310 |
|
|
------ |
|
------ |
------ |
------ |
|
|
1,316 |
|
(260) |
1,056 |
1,346 |
|
|
------ |
|
------ |
--- |
------ |
|
|
|
|
|
|
|
|
EARNINGS PER SHARE |
25.2p |
(9) |
|
20.1p |
23.7p |
|
|
------ |
|
|
------ |
------ |
|
|
|
|
|
|
|
|
Diluted earnings per share |
25.0p |
|
|
20.0p |
23.5p |
|
|
------ |
|
|
------ |
------ |
|
Turnover |
|
|
|
Pharmaceuticals including vaccines Three months ended 30th September 2008 |
|
|
Total |
USA |
Europe |
Rest of World |
||||
|
|
-------------- |
-------------- |
-------------- |
------------- |
||||
|
|
£m |
CER% |
£m |
CER% |
£m |
CER% |
£m |
CER% |
|
|
------ |
----- |
------ |
----- |
----- |
----- |
---- |
----- |
|
Respiratory |
1,348 |
3 |
636 |
3 |
449 |
- |
263 |
11 |
|
Seretide/Advair |
982 |
7 |
515 |
5 |
324 |
1 |
143 |
35 |
|
Flixotide/Flovent |
149 |
(4) |
71 |
(1) |
38 |
(3) |
40 |
(10) |
|
Serevent |
60 |
(14) |
17 |
(11) |
32 |
(13) |
11 |
(23) |
|
Veramyst |
17 |
>100 |
12 |
>100 |
3 |
- |
2 |
- |
|
Flixonase/Flonase |
33 |
(39) |
7 |
(67) |
11 |
11 |
15 |
(32) |
|
|
|
|
|
|
|
|
|
|
|
Anti-virals |
792 |
1 |
398 |
5 |
199 |
(12) |
195 |
7 |
|
HIV |
377 |
(5) |
153 |
(11) |
150 |
(6) |
74 |
11 |
|
Epzicom/Kivexa |
110 |
24 |
44 |
21 |
50 |
19 |
16 |
56 |
|
Combivir |
110 |
(13) |
41 |
(26) |
38 |
(19) |
31 |
26 |
|
Trizivir |
49 |
(20) |
24 |
(21) |
22 |
(17) |
3 |
(25) |
|
Agenerase, Lexiva |
40 |
(3) |
21 |
(5) |
15 |
(8) |
4 |
25 |
|
Epivir |
35 |
(16) |
11 |
(29) |
13 |
(27) |
11 |
22 |
|
Ziagen |
27 |
(11) |
10 |
(17) |
8 |
(22) |
9 |
14 |
|
|
|
|
|
|
|
|
|
|
|
Valtrex |
303 |
21 |
223 |
28 |
35 |
7 |
45 |
3 |
|
|
|
|
|
|
|
|
|
|
|
Zeffix |
42 |
(10) |
4 |
(25) |
7 |
- |
31 |
(9) |
|
Relenza |
12 |
(57) |
5 |
(58) |
- |
- |
7 |
>100 |
|
|
|
|
|
|
|
|
|
|
|
Central nervous system |
585 |
(38) |
321 |
(52) |
142 |
4 |
122 |
(5) |
|
Lamictal |
136 |
(59) |
84 |
(71) |
37 |
(9) |
15 |
- |
|
Imigran/Imitrex |
188 |
5 |
154 |
8 |
24 |
(5) |
10 |
- |
|
Seroxat/Paxil |
112 |
(23) |
13 |
(67) |
27 |
(8) |
72 |
(9) |
|
Wellbutrin |
53 |
(67) |
44 |
(72) |
6 |
100 |
3 |
100 |
|
Requip |
56 |
(43) |
13 |
(81) |
35 |
35 |
8 |
60 |
|
Requip XL |
15 |
- |
4 |
- |
11 |
- |
- |
- |
|
Treximet |
4 |
- |
4 |
- |
- |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Cardiovascular and urogenital |
466 |
12 |
280 |
9 |
130 |
17 |
56 |
13 |
|
Avodart |
102 |
29 |
63 |
29 |
29 |
19 |
10 |
67 |
|
Lovaza |
75 |
- |
75 |
- |
- |
- |
- |
- |
|
Coreg |
50 |
(69) |
49 |
(69) |
- |
- |
1 |
(100) |
|
Coreg CR |
41 |
19 |
41 |
19 |
- |
- |
- |
- |
|
Coreg IR |
9 |
(93) |
8 |
(93) |
- |
- |
1 |
(100) |
|
Fraxiparine |
59 |
22 |
- |
- |
47 |
18 |
12 |
38 |
|
Arixtra |
44 |
56 |
22 |
43 |
19 |
78 |
3 |
50 |
|
Vesicare |
18 |
31 |
18 |
31 |
- |
- |
- |
- |
|
Levitra |
16 |
15 |
15 |
17 |
1 |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Metabolic |
289 |
(11) |
136 |
(22) |
72 |
(2) |
81 |
4 |
|
Avandia products |
191 |
(23) |
99 |
(28) |
48 |
(16) |
44 |
(16) |
|
Avandia |
118 |
(29) |
67 |
(33) |
20 |
(31) |
31 |
(20) |
|
Avandamet |
63 |
(7) |
26 |
(14) |
26 |
- |
11 |
- |
|
Bonviva/Boniva |
56 |
24 |
36 |
18 |
18 |
60 |
2 |
(33) |
|
|
|
|
|
|
|
|
|
|
|
Anti-bacterials |
340 |
3 |
40 |
(10) |
141 |
(1) |
159 |
10 |
|
Augmentin |
143 |
10 |
9 |
(36) |
62 |
6 |
72 |
24 |
|
Altabax |
5 |
>100 |
4 |
100 |
1 |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Oncology and emesis |
128 |
12 |
64 |
13 |
41 |
6 |
23 |
16 |
|
Hycamtin |
34 |
3 |
20 |
- |
12 |
10 |
2 |
- |
|
Zofran |
33 |
(9) |
6 |
50 |
15 |
(24) |
12 |
(9) |
|
Tykerb |
26 |
44 |
12 |
- |
10 |
80 |
4 |
- |
|
|
|
|
|
|
|
|
|
|
|
Vaccines |
730 |
12 |
218 |
(13) |
323 |
40 |
189 |
12 |
|
Hepatitis |
174 |
11 |
82 |
17 |
61 |
2 |
31 |
19 |
|
Infanrix/Pediarix |
168 |
9 |
56 |
(10) |
89 |
23 |
23 |
28 |
|
Fluarix, FluLaval |
144 |
11 |
63 |
(19) |
58 |
55 |
23 |
100 |
|
Flu-prepandemic |
10 |
(52) |
- |
- |
10 |
>100 |
- |
- |
|
Cervarix |
43 |
>100 |
- |
- |
38 |
- |
5 |
>100 |
|
Rotarix |
39 |
57 |
4 |
- |
11 |
67 |
24 |
29 |
|
Boostrix |
22 |
(19) |
13 |
(40) |
7 |
40 |
2 |
100 |
|
|
|
|
|
|
|
|
|
|
|
Other |
210 |
(3) |
8 |
>100 |
66 |
(6) |
136 |
(12) |
|
|
------ |
---- |
------ |
---- |
------ |
---- |
----- |
---- |
|
|
4,888 |
(4) |
2,101 |
(13) |
1,563 |
6 |
1,224 |
5 |
|
|
------ |
---- |
------ |
---- |
------ |
---- |
----- |
---- |
|
Pharmaceutical turnover includes co-promotion income. |
||||||||
|
Regional pharmaceuticals including vaccines |
|
|
Q3 2008 |
||
|
|
-------------- |
||
|
|
£m |
CER% |
|
|
|
------ |
----- |
|
|
USA |
2,101 |
(13) |
|
|
Europe |
1,563 |
6 |
|
|
Rest of World |
1,224 |
5 |
|
|
|
Asia Pacific/Japan |
464 |
5 |
|
|
Emerging markets |
581 |
9 |
|
|
|
------ |
---- |
|
|
|
4,888 |
(4) |
|
|
|
------ |
---- |
|
Turnover |
|
Consumer Healthcare |
|
|
Total |
USA |
Europe |
Rest of World |
||||
|
|
-------------- |
-------------- |
-------------- |
------------- |
||||
|
|
£m |
CER% |
£m |
CER% |
£m |
CER% |
£m |
CER% |
|
|
------ |
----- |
------ |
----- |
------ |
----- |
------ |
----- |
|
|
|
|
|
|
|
|
|
|
|
Over-the-counter medicines |
476 |
(1) |
155 |
(16) |
142 |
4 |
179 |
13 |
|
Panadol franchise |
82 |
9 |
- |
- |
20 |
(6) |
62 |
14 |
|
Smoking cessation products |
83 |
3 |
60 |
2 |
13 |
(8) |
10 |
33 |
|
Tums |
21 |
(17) |
18 |
(16) |
- |
- |
3 |
- |
|
Cold sore franchise |
22 |
- |
10 |
(9) |
8 |
- |
4 |
50 |
|
Breathe Right |
19 |
(5) |
13 |
(8) |
4 |
100 |
2 |
(50) |
|
Alli |
18 |
(50) |
18 |
(50) |
- |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Oral healthcare |
310 |
7 |
54 |
4 |
174 |
7 |
82 |
9 |
|
Aquafresh franchise |
116 |
5 |
20 |
6 |
72 |
2 |
24 |
15 |
|
Sensodyne franchise |
90 |
8 |
17 |
14 |
43 |
9 |
30 |
4 |
|
Dental healthcare |
68 |
9 |
15 |
- |
27 |
15 |
26 |
9 |
|
|
|
|
|
|
|
|
|
|
|
Nutritional healthcare |
208 |
5 |
- |
- |
127 |
1 |
81 |
13 |
|
Lucozade |
100 |
2 |
- |
- |
89 |
- |
11 |
25 |
|
Horlicks |
53 |
10 |
- |
- |
5 |
(17) |
48 |
14 |
|
Ribena |
44 |
2 |
- |
- |
33 |
(3) |
11 |
25 |
|
|
------ |
---- |
------ |
---- |
------ |
---- |
------ |
---- |
|
|
994 |
3 |
209 |
(11) |
443 |
4 |
342 |
12 |
|
|
------ |
---- |
------ |
---- |
------ |
---- |
------ |
---- |
|
GSK's late-stage pharmaceuticals and vaccines pipeline |
|
|
|
The following table is provided as part of GSK's quarterly update to show events and changes to the late stage pipeline during the quarter and up to the date of announcement. |
|
Biopharmaceuticals
|
USA
|
EU
|
News update in the quarter
|
|
|
Bosatria
|
HES
|
Ph III
|
Filed
Sept 2008 |
Filed in EU on 5th September.
|
|
belimumab
|
Lupus
|
Ph III
|
Ph III
|
|
|
ofatumumab
|
CLL / NHL
|
Ph III
|
Ph III
|
Announced positive interim results of CLL study (406) on 31st July.
|
|
RA
|
Ph III
|
Ph III
|
|
|
|
otelixizumab
|
Type 1 diabetes
|
Ph III
|
Ph III
|
Ph III study started in August.
|
|
|
|
|
|
|
|
Cardiovascular & Metabolic
|
USA
|
EU
|
News update in the quarter
|
|
|
Arixtra
|
Acute Coronary Syndromes
|
Filed
|
Approved
Aug 2007 |
|
|
Volibris
|
PAH Class II/III
|
n/a
|
Approved
April 2008 |
|
|
Avandamet XR
|
Type II diabetes
|
Ph III
|
Ph III
|
Filing strategy under review.
|
|
Avandia + statin
|
Type II diabetes
|
Ph III
|
Ph III
|
Filing strategy under review.
|
|
Coreg CR + ACEi
|
Hypertension
|
Ph III
|
n/a
|
Filing strategy under review.
|
|
|
|
|
|
|
|
Neurosciences
|
|
USA
|
EU
|
News update in the quarter
|
|
Requip XL
|
Parkinson's disease
|
Approved
June 2008 |
Approved
Mar 2007 |
|
|
Treximet
|
Migraine
|
Approved
April 2008 |
n/a
|
Filed sNDA for ‘probable migraine’ 23rd September.
|
|
Lamictal XR
|
Epilepsy
|
Filed
|
n/a
|
|
|
Lunivia
|
Sleep disorders
|
n/a
|
Filed
|
|
|
Solzira
|
RLS
|
Filed
|
Ph III
|
Filed with FDA on 16th September.
|
|
almorexant
|
Primary insomnia
|
Ph III
|
Ph III
|
Collaboration with Actelion announced 14th July
|
|
retigabine
|
Epilepsy
|
Ph III
|
Ph III
|
Collaboration with Valeant announced on 28th August.
|
|
rosiglitazone XR
|
Alzheimer's disease
|
Ph III
|
Ph III
|
|
|
|
|
|
|
|
|
Oncology
|
|
USA
|
EU
|
News update in the quarter
|
|
Tykerb/Tyverb
|
Refractory breast cancer
|
Approved
Mar 2007 |
Approved
June 2008 |
|
|
First-line / Adjuvant breast cancer
|
Ph III
|
Ph III
|
|
|
|
Head & neck cancer
|
Ph III
|
Ph III
|
|
|
|
Gastric Cancer
|
Ph III
|
Ph III
|
Ph III study started in September.
|
|
|
Avodart
|
Co-Rx with tamsulosin
|
Approved
June 2008 |
Approved
April 2008 |
|
|
Prostate cancer prevention
|
Ph III
|
Ph III
|
|
|
|
Fixed dose combination with tamsulosin
|
Ph III
|
Ph III
|
|
|
|
Rezonic/Zunrisa
|
CINV/PONV
|
Filed
May 2008 |
Filed
July 2008 |
|
|
|
|
|
|
|
|
Oncology / contd.
|
USA
|
EU
|
News update in the quarter
|
|
|
Promacta/Revolade
|
Short term ITP
|
Filed
|
Ph III
|
FDA PDUFA extended beyond 19th September.
|
|
Long term ITP
|
Ph III
|
Ph III
|
|
|
|
Hepatitis C / CLD
|
Ph III
|
Ph III
|
|
|
|
Armala
|
Renal cell cancer
|
Ph III
|
Ph III
|
Ph II data presented at ESMO in September.
|
|
Sarcoma
|
Ph III
|
Ph III
|
Ph II data presented at ESMO in September.
Ph III study started in October.
|
|
|
Armala + Tykerb
|
Inflammatory breast cancer
|
Ph III
|
Ph III
|
|
|
elesclomol
|
Metastatic melanoma
|
Ph III
|
Ph III
|
Ph II data presented at ESMO in September.
|
|
|
|
|
|
|
|
Respiratory & Immuno-inflammation
|
USA
|
EU
|
News update in the quarter
|
|
|
Seretide/Advair
|
COPD exacerbation claim
|
Approved
April 2008 |
Already in label
|
|
|
Entereg
|
Post operative ileus
|
Approved
May 2008 |
n/a
|
Returned OBD rights to Adolor 2nd September.
|
|
|
|
|
|
|
|
Vaccines
|
|
USA
|
EU
|
News update in the quarter
|
|
Rotarix
|
Rotavirus prophylaxis
|
Approved
April 2008 |
Approved
Feb 2006 |
US vaccines for Children (VFC) funding commenced on 4th August.
|
|
Kinrix
|
DTaP-IPV prophylaxis
|
Approved
June 2008 |
n/a
|
US VFC funding commenced on 4th August.
|
|
Cervarix
|
HPV prophylaxis
|
Filed
|
Approved
Sep 2007 |
|
|
Prepandrix
|
H5N1 pandemic influenza prophylaxis
|
Ph III
|
Approved
May 2008 |
|
|
Synflorix
|
S pneumoniae and NTHi prophylaxis
|
Ph III
|
Filed
|
US filing strategy under review.
|
|
MAGE-A3
|
NSCLC
|
Ph III
|
Ph III
|
|
|
HibMenCY-TT
|
MenCY and Hib prophylaxis
|
Ph III
|
n/a
|
|
|
MenACWY
|
MenACWY prophylaxis
|
Ph III
|
Ph III
|
|
|
New generation flu
|
Influenza prophylaxis
|
Ph III
|
Ph III
|
Large multi-centre international efficacy study in 43,000 subjects began in September.
|
|
Simplirix
|
Genital herpes prophylaxis
|
Ph III
|
Ph III
|
|
|
Balance sheet |
|
|
30th September |
30th September |
31st December |
|
ASSETS |
---- |
---- |
---- |
|
Non-current assets |
|
|
|
|
Property, plant and equipment |
8,395 |
7,464 |
7,821 |
|
Goodwill |
1,747 |
985 |
1,370 |
|
Other intangible assets |
4,944 |
3,721 |
4,456 |
|
Investments in associates and joint ventures |
445 |
313 |
329 |
|
Other investments |
454 |
533 |
517 |
|
Deferred tax assets |
2,439 |
2,278 |
2,196 |
|
Derivative financial instruments |
17 |
132 |
1 |
|
Other non-current assets |
465 |
862 |
687 |
|
|
---- |
---- |
---- |
|
Total non-current assets |
18,906 |
16,288 |
17,377 |
|
|
---- |
---- |
---- |
|
Current assets |
|
|
|
|
Inventories |
3,515 |
2,965 |
3,062 |
|
Current tax recoverable |
50 |
159 |
58 |
|
Trade and other receivables |
5,483 |
5,030 |
5,495 |
|
Derivative financial instruments |
349 |
89 |
475 |
|
Liquid investments |
401 |
1,084 |
1,153 |
|
Cash and cash equivalents |
5,148 |
2,050 |
3,379 |
|
Assets held for sale |
8 |
4 |
4 |
|
|
---- |
---- |
---- |
|
Total current assets |
14,954 |
11,381 |
13,626 |
|
|
---- |
---- |
---- |
|
TOTAL ASSETS |
33,860 |
27,669 |
31,003 |
|
|
---- |
---- |
---- |
|
LIABILITIES |
|
|
|
|
Current liabilities |
|
|
|
|
Short-term borrowings |
(1,387) |
(1,994) |
(3,504) |
|
Trade and other payables |
(5,143) |
(5,142) |
(4,861) |
|
Derivative financial instruments |
(195) |
(75) |
(262) |
|
Current tax payable |
(1,058) |
(1,217) |
(826) |
|
Short-term provisions |
(1,015) |
(601) |
(892) |
|
|
---- |
---- |
---- |
|
Total current liabilities |
(8,798) |
(9,029) |
(10,345) |
|
|
---- |
---- |
---- |
|
Non-current liabilities |
|
|
|
|
Long-term borrowings |
(12,801) |
(4,885) |
(7,067) |
|
Deferred tax liabilities |
(652) |
(831) |
(887) |
|
Pensions and other post-employment benefits |
(2,312) |
(1,331) |
(1,383) |
|
Other provisions |
(1,129) |
(1,002) |
(1,035) |
|
Derivative financial instruments |
- |
(72) |
(8) |
|
Other non-current liabilities |
(371) |
(357) |
(368) |
|
|
---- |
---- |
---- |
|
Total non-current liabilities |
(17,265) |
(8,478) |
(10,748) |
|
|
---- |
---- |
---- |
|
TOTAL LIABILITIES |
(26,063) |
(17,507) |
(21,093) |
|
|
---- |
---- |
---- |
|
NET ASSETS |
7,797 |
10,162 |
9,910 |
|
|
---- |
---- |
---- |
|
|
|
|
|
|
EQUITY |
|
|
|
|
Share capital |
1,423 |
1,506 |
1,503 |
|
Share premium account |
1,322 |
1,218 |
1,266 |
|
Retained earnings |
4,099 |
6,818 |
6,475 |
|
Other reserves |
642 |
337 |
359 |
|
|
---- |
---- |
---- |
|
Shareholders' equity |
7,486 |
9,879 |
9,603 |
|
|
|
|
|
|
Minority interests |
311 |
283 |
307 |
|
|
---- |
---- |
---- |
|
TOTAL EQUITY |
7,797 |
10,162 |
9,910 |
|
|
---- |
---- |
---- |
|
Net assets The book value of net assets decreased by £2,113 million from £9,910 million at 31st December 2007 to £7,797 million at 30th September 2008. This reflects an increase in net debt arising from the funding of the share buy-back programme and dividend payments, together with an increase in the pension deficit. The increase in the pension deficit arose predominantly from a reduction in asset values and an increase in the estimated long-term UK inflation rate, partially offset by an increase in the rate used to discount UK pension liabilities from 5.75% to 6.50%. At 30th September 2008, the net deficit on the Group's pension plans was £1,192 million compared with a net deficit at 31st December 2007 of £156 million. The carrying value of investments in associates and joint ventures at 30th September 2008 was £445 million, with a market value of £1,146 million. In Q3 2008, GSK repurchased and cancelled £865 million of shares. The number of shares in issue at 30th September 2008, excluding those held by the ESOP Trusts and those held as Treasury shares, was 5,089 million (30th September 2007: 5,465 million). |
|
Legal matters The Group is involved in various legal and administrative proceedings principally product liability, intellectual property, tax, anti-trust and governmental investigations and related private litigation concerning sales, marketing and pricing which are more fully described in the 'Legal proceeding' note in the Annual Report 2007. At 30th September 2008, the Group's aggregate provision for legal and other disputes (not including tax matters described under 'Taxation' on page 15) was £1.2 billion. The ultimate liability for legal claims may vary from the amounts provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations. Significant developments since the date of the Annual Report 2007 (as previously updated by the legal matters section of the Results Announcements for Q1 and Q2 2008) are as follows: With respect to the Group's action against Teva Pharmaceuticals relating to the Group's combination patent regarding Combivir, the Group received an additional certification in October 2008 related to Teva's ANDA for Combivir alleging that the Group's patent covering the crystal form of lamivudine, one of the active ingredients in Combivir, is invalid or not infringed. The patent expires in 2016. The Group is evaluating the certification. Teva has not challenged the Group patent relating to Combivir that expires in 2010. |
|
In October 2008, the Group received a letter from Par Pharmaceuticals confirming that the FDA has accepted its ANDA for Treximet, which included a certification of invalidity, unenforceability and/or non-infringement of several patents covering Treximet that are owned by Pozen and licensed to the Group. Pozen has the right to bring actions for infringement of these patents. Treximet has data exclusivity until April 2011. |
|
With respect to the private indirect purchaser opt-out lawsuit brought in the Minnesota state courts relating to Paxil, such lawsuit has been settled. The terms of the settlement are confidential. With respect to the complaint filed against Biovail and GSK by a purported class of direct purchasers alleging anti-trust violations relating to the enforcement of Biovail's Wellbutrin XL patents, a separate complaint has also been filed against the Group and Biovail by a purported class of indirect purchasers. Each of the Group and Biovail has filed motions to dismiss both of the complaints. With respect to the Avandia securities litigation, the Group's motion to dismiss the complaint was granted and the trial court subsequently denied the plaintiffs' motion for reconsideration. The plaintiffs have filed a notice of appeal with the US Court of Appeals for the Second Circuit. The Group plans to respond to the appeal. Developments with respect to tax matters are described in 'Taxation' on page15. |
|
Taxation Transfer pricing and other issues are as previously described in the 'Taxation' note to the Financial Statements included in the Annual Report 2007. In relation to the dispute with the IRS regarding deductions arising from inter-company financing arrangements, GSK received a Notice of Deficiency against which it filed a petition in the US Tax Court on 4th August. There have been no material changes to other tax matters since the publication of the Results Announcement for Q2 2008. |
|
As expected, the tax rate on business performance profit for Q3 2008 rose to 29.8% reflecting the cumulative effect of changes in the recently enacted UK Finance Act relating to restrictions on tax allowances. The year-to-date business performance rate of 29% is more indicative of the expected full-year tax charge. GSK uses the best advice in determining its transfer pricing methodology and in seeking to manage all of its tax affairs to a satisfactory conclusion and, based on external professional advice, continues to believe that it has made adequate provision for the liabilities likely to arise from open assessments. The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of litigation proceedings and negotiations with the relevant tax authorities. |
|
Accounting presentation and policies This unaudited Results Announcement containing condensed financial information for the three and nine months ended 30th September 2008 is prepared in accordance with the Disclosure and Transparency Rules of the United Kingdom's Financial Services Authority and the accounting policies set out in the Annual Report 2007. This Results Announcement does not constitute statutory accounts of the Group within the meaning of section 240 of the Companies Act 1985. The balance sheet at 31st December 2007 has been derived from the full Group accounts published in the Annual Report 2007, which has been delivered to the Registrar of Companies and on which the report of the independent auditors was unqualified and did not contain a statement under either section 237(2) or section 237(3) of the Companies Act 1985. |
|
Comparative information restatement As reported in the Results Announcement for Q2 2008 the regional reporting structure within the Pharmaceuticals business has been realigned together with the allocation of entities and expenses between the Pharmaceuticals and Consumer Healthcare businesses. As a result, comparative information has been restated onto a consistent basis and the effect of the restatements on each quarter in 2007 and on Q1 2008 is available on the company's website. These reallocations have no impact on Group turnover or Group operating profit. |
|
Dividends |
Paid/ |
Pence per |
|
|
|
|
|
---- |
---- |
---- |
|
2008 |
|
|
|
|
|
First interim |
10th July 2008 |
13 |
683 |
|
|
Second interim |
9th October 2008 |
13 |
679 |
|
|
Third interim |
8th January 2009 |
14 |
712 |
|
|
|
|
|
|
|
|
2007 |
|
|
|
|
|
First interim |
12th July 2007 |
12 |
670 |
|
|
Second interim |
11th October 2007 |
12 |
667 |
|
|
Third interim |
10th January 2008 |
13 |
708 |
|
|
Fourth interim |
10th April 2008 |
16 |
859 |
|
|
|
|
|
---- |
---- |
|
|
|
|
53 |
2,904 |
|
|
|
|
---- |
---- |
|
Income statement |
|
Nine months ended 30th September 2008 |
|
|
Business |
Growth |
Restructuring |
|
|
|
|
£m |
CER% |
£m |
£m |
£m |
|
|
--- |
--- |
--- |
--- |
--- |
|
Turnover: |
|
|
|
|
|
|
Pharmaceuticals |
14,578 |
(3) |
|
14,578 |
14,136 |
|
Consumer Healthcare |
2,864 |
3 |
|
2,864 |
2,606 |
|
|
--- |
|
|
--- |
--- |
|
TURNOVER |
17,442 |
(2) |
|
17,442 |
16,742 |
|
|
|
|
|
|
|
|
Cost of sales |
(4,134) |
6 |
(328) |
(4,462) |
(3,678) |
|
|
--- |
|
--- |
--- |
--- |
|
Gross profit |
13,308 |
(5) |
(328) |
12,980 |
13,064 |
|
|
|
|
|
|
|
|
Selling, general and administration |
(5,147) |
(5) |
(213) |
(5,360) |
(5,131) |
|
Research and development |
(2,416) |
2 |
(53) |
(2,469) |
(2,284) |
|
Other operating income |
408 |
|
|
408 |
356 |
|
|
--- |
|
--- |
--- |
--- |
|
|
|
|
|
|
|
|
Operating profit: |
|
|
|
|
|
|
Pharmaceuticals |
5,609 |
(6) |
(581) |
5,028 |
5,504 |
|
Consumer Healthcare |
544 |
(4) |
(13) |
531 |
501 |
|
|
--- |
|
--- |
--- |
--- |
|
OPERATING PROFIT |
6,153 |
(6) |
(594) |
5,559 |
6,005 |
|
|
|
|
|
|
|
|
Finance income |
276 |
|
|
276 |
210 |
|
Finance expense |
(600) |
|
(2) |
(602) |
(334) |
|
Share of after tax profits of associates |
30 |
|
|
30 |
40 |
|
|
--- |
|
--- |
--- |
--- |
|
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION |
5,859 |
(10) |
(596) |
5,263 |
5,921 |
|
|
|
|
|
|
|
|
Taxation |
(1,699) |
|
131 |
(1,568) |
(1,687) |
|
Tax rate % |
29.0% |
|
|
29.8% |
28.5% |
|
|
--- |
|
--- |
--- |
--- |
|
PROFIT AFTER TAXATION FOR THE PERIOD |
4,160 |
(10) |
(465) |
3,695 |
4,234 |
|
|
--- |
|
--- |
--- |
--- |
|
|
|
|
|
|
|
|
Profit attributable to minority interests |
75 |
|
|
75 |
77 |
|
Profit attributable to shareholders |
4,085 |
|
(465) |
3,620 |
4,157 |
|
|
--- |
|
--- |
--- |
--- |
|
|
4,160 |
|
(465) |
3,695 |
4,234 |
|
|
--- |
|
--- |
--- |
--- |
|
|
|
|
|
|
|
|
EARNINGS PER SHARE |
78.0p |
(5) |
|
69.2p |
74.7p |
|
|
--- |
|
|
--- |
--- |
|
|
|
|
|
|
|
|
Diluted earnings per share |
77.5p |
|
|
68.7p |
73.9p |
|
|
--- |
|
|
--- |
--- |
|
Turnover |
|
|
|
Pharmaceuticals including vaccines Nine months ended 30th September 2008 |
|
|
Total |
USA |
Europe |
Rest of World |
||||
|
|
-------------- |
-------------- |
-------------- |
------------- |
||||
|
|
£m |
CER% |
£m |
CER% |
£m |
CER% |
£m |
CER% |
|
|
------ |
----- |
------ |
----- |
----- |
----- |
---- |
----- |
|
Respiratory |
4,086 |
4 |
1,868 |
5 |
1,432 |
1 |
786 |
10 |
|
Seretide/Advair |
2,900 |
8 |
1,487 |
6 |
1,024 |
4 |
389 |
29 |
|
Flixotide/Flovent |
469 |
(2) |
214 |
3 |
125 |
(6) |
130 |
(9) |
|
Serevent |
193 |
(10) |
50 |
(11) |
103 |
(6) |
40 |
(18) |
|
Veramyst |
47 |
>100 |
38 |
>100 |
5 |
- |
4 |
>100 |
|
Flixonase/Flonase |
144 |
(20) |
44 |
(38) |
40 |
(3) |
60 |
(8) |
|
|
|
|
|
|
|
|
|
|
|
Anti-virals |
2,282 |
(4) |
1,100 |
(2) |
626 |
(14) |
556 |
4 |
|
HIV |
1,096 |
(6) |
447 |
(9) |
471 |
(5) |
178 |
3 |
|
Epzicom/Kivexa |
313 |
24 |
123 |
14 |
152 |
28 |
38 |
52 |
|
Combivir |
319 |
(14) |
127 |
(17) |
124 |
(20) |
68 |
8 |
|
Trizivir |
153 |
(20) |
74 |
(21) |
70 |
(16) |
9 |
(33) |
|
Agenerase, Lexiva |
113 |
1 |
57 |
(5) |
46 |
3 |
10 |
43 |
|
Epivir |
103 |
(19) |
33 |
(20) |
43 |
(22) |
27 |
(13) |
|
Ziagen |
78 |
(9) |
31 |
(9) |
27 |
(11) |
20 |
(5) |
|
|
|
|
|
|
|
|
|
|
|
Valtrex |
829 |
16 |
591 |
19 |
106 |
11 |
132 |
9 |
|
|
|
|
|
|
|
|
|
|
|
Zeffix |
135 |
(1) |
11 |
- |
20 |
6 |
104 |
(2) |
|
Relenza |
44 |
(78) |
15 |
(83) |
1 |
(99) |
28 |
- |
|
|
|
|
|
|
|
|
|
|
|
Central nervous system |
2,232 |
(13) |
1,462 |
(18) |
414 |
(1) |
356 |
(4) |
|
Lamictal |
749 |
(9) |
592 |
(10) |
108 |
(9) |
49 |
2 |
|
Imigran/Imitrex |
526 |
2 |
427 |
3 |
71 |
(3) |
28 |
(4) |
|
Seroxat/Paxil |
360 |
(19) |
60 |
(42) |
86 |
(15) |
214 |
(8) |
|
Wellbutrin |
276 |
(33) |
254 |
(36) |
12 |
>100 |
10 |
11 |
|
Requip |
208 |
(22) |
91 |
(48) |
95 |
29 |
22 |
82 |
|
Requip XL |
23 |
- |
4 |
- |
19 |
- |
- |
- |
|
Treximet |
12 |
- |
12 |
- |
- |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Cardiovascular and urogenital |
1,299 |
(3) |
763 |
(10) |
375 |
12 |
161 |
15 |
|
Avodart |
279 |
31 |
167 |
29 |
85 |
25 |
27 |
63 |
|
Lovaza |
192 |
- |
191 |
- |
- |
- |
1 |
- |
|
Coreg |
142 |
(76) |
140 |
(75) |
- |
- |
2 |
(83) |
|
Coreg CR |
115 |
>100 |
114 |
>100 |
- |
- |
1 |
- |
|
Coreg IR |
27 |
(95) |
26 |
(95) |
- |
- |
1 |
(100) |
|
Fraxiparine |
168 |
10 |
- |
- |
134 |
4 |
34 |
39 |
|
Arixtra |
115 |
51 |
57 |
44 |
50 |
54 |
8 |
100 |
|
Vesicare |
48 |
31 |
48 |
31 |
- |
- |
- |
- |
|
Levitra |
43 |
11 |
41 |
11 |
2 |
100 |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Metabolic |
846 |
(33) |
408 |
(45) |
218 |
(9) |
220 |
(17) |
|
Avandia products |
576 |
(45) |
302 |
(54) |
151 |
(21) |
123 |
(33) |
|
Avandia |
365 |
(51) |
210 |
(58) |
62 |
(36) |
93 |
(36) |
|
Avandamet |
186 |
(25) |
75 |
(39) |
85 |
(6) |
26 |
(15) |
|
Bonviva/Boniva |
161 |
39 |
105 |
34 |
51 |
55 |
5 |
33 |
|
|
|
|
|
|
|
|
|
|
|
Anti-bacterials |
1,032 |
- |
124 |
(15) |
456 |
(4) |
452 |
9 |
|
Augmentin |
428 |
2 |
34 |
(37) |
198 |
2 |
196 |
16 |
|
Altabax |
11 |
57 |
10 |
43 |
1 |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Oncology and emesis |
358 |
(11) |
179 |
(23) |
119 |
6 |
60 |
10 |
|
Hycamtin |
99 |
6 |
56 |
4 |
35 |
7 |
8 |
17 |
|
Zofran |
93 |
(52) |
13 |
(85) |
47 |
(23) |
33 |
(17) |
|
Tykerb |
67 |
94 |
33 |
38 |
25 |
>100 |
9 |
- |
|
|
|
|
|
|
|
|
|
|
|
Vaccines |
1,743 |
18 |
451 |
4 |
799 |
30 |
493 |
16 |
|
Hepatitis |
480 |
17 |
201 |
36 |
189 |
1 |
90 |
16 |
|
Infanrix/Pediarix |
488 |
10 |
156 |
1 |
264 |
15 |
68 |
14 |
|
Fluarix, FluLaval |
149 |
10 |
63 |
(18) |
57 |
56 |
29 |
53 |
|
Flu-prepandemic |
49 |
>100 |
- |
- |
49 |
>100 |
- |
- |
|
Cervarix |
70 |
>100 |
- |
- |
59 |
- |
11 |
>100 |
|
Rotarix |
101 |
81 |
4 |
- |
30 |
63 |
67 |
78 |
|
Boostrix |
53 |
(6) |
27 |
(24) |
19 |
21 |
7 |
40 |
|
|
|
|
|
|
|
|
|
|
|
Other |
700 |
1 |
13 |
(63) |
218 |
11 |
469 |
2 |
|
|
------ |
---- |
------ |
---- |
------ |
---- |
----- |
---- |
|
|
14,578 |
(3) |
6,368 |
(11) |
4,657 |
3 |
3,553 |
5 |
|
|
------ |
---- |
------ |
---- |
------ |
---- |
----- |
---- |
|
Pharmaceutical turnover includes co-promotion income. |
||||||||
|
Regional pharmaceuticals including vaccines |
|
|
9 months 2008 |
||
|
|
-------------- |
||
|
|
£m |
CER% |
|
|
|
------ |
----- |
|
|
USA |
6,368 |
(11) |
|
|
Europe |
4,657 |
3 |
|
|
Rest of World |
3,553 |
5 |
|
|
|
Asia Pacific/Japan |
1,348 |
1 |
|
|
Emerging markets |
1,613 |
10 |
|
|
|
------ |
---- |
|
|
|
14,578 |
(3) |
|
|
|
------ |
---- |
|
Turnover |
|
Consumer Healthcare Nine months ended 30th September 2008 |
|
|
Total |
USA |
Europe |
Rest of World |
||||
|
|
-------------- |
-------------- |
-------------- |
--------------- |
||||
|
|
£m |
CER% |
£m |
CER% |
£m |
CER% |
£m |
CER% |
|
|
------ |
----- |
------ |
----- |
----- |
----- |
------ |
------ |
|
|
|
|
|
|
|
|
|
|
|
Over-the-counter medicines |
1,356 |
(2) |
423 |
(19) |
420 |
4 |
513 |
14 |
|
Panadol franchise |
240 |
13 |
- |
- |
56 |
7 |
184 |
15 |
|
Smoking cessation products |
206 |
(13) |
145 |
(10) |
42 |
(28) |
19 |
6 |
|
Tums |
64 |
(6) |
55 |
(7) |
- |
(100) |
9 |
14 |
|
Cold sore franchise |
61 |
8 |
26 |
4 |
27 |
9 |
8 |
17 |
|
Breathe Right |
54 |
13 |
32 |
(11) |
14 |
>100 |
8 |
40 |
|
Alli |
45 |
(60) |
43 |
(61) |
- |
- |
2 |
100 |
|
|
|
|
|
|
|
|
|
|
|
Oral healthcare |
897 |
6 |
154 |
- |
502 |
6 |
241 |
10 |
|
Aquafresh franchise |
330 |
3 |
58 |
(3) |
202 |
2 |
70 |
10 |
|
Sensodyne franchise |
263 |
12 |
47 |
12 |
127 |
13 |
89 |
11 |
|
Dental healthcare |
194 |
7 |
44 |
(2) |
78 |
11 |
72 |
10 |
|
|
|
|
|
|
|
|
|
|
|
Nutritional healthcare |
611 |
10 |
- |
- |
371 |
5 |
240 |
19 |
|
Lucozade |
293 |
10 |
- |
- |
260 |
8 |
33 |
29 |
|
Horlicks |
157 |
14 |
- |
- |
16 |
(11) |
141 |
18 |
|
Ribena |
124 |
1 |
- |
- |
94 |
(2) |
30 |
12 |
|
|
------ |
---- |
------ |
---- |
------ |
---- |
------ |
----- |
|
|
2,864 |
3 |
577 |
(15) |
1,293 |
5 |
994 |
14 |
|
|
------ |
---- |
------ |
---- |
------ |
---- |
------ |
----- |
|
Cash flow statement |
|
Nine months ended 30th September 2008 |
|
|
9 Months 2008 |
9 Months 2007 |
2007 |
|
|
|
---- |
---- |
---- |
|
|
Profit after tax |
3,695 |
4,234 |
5,310 |
|
|
Tax on profits |
1,568 |
1,687 |
2,142 |
|
|
Share of after tax profits of associates and joint ventures |
(30) |
(40) |
(50) |
|
|
Net finance expense |
326 |
124 |
191 |
|
|
Depreciation and other non-cash items |
993 |
920 |
1,333 |
|
|
Increase in working capital |
(207) |
(373) |
(538) |
|
|
Increase/(decrease) in other net liabilities |
133 |
(400) |
(308) |
|
|
|
---- |
---- |
---- |
|
|
Cash generated from operations |
6,478 |
6,152 |
8,080 |
|
|
|
|
|
|
|
|
Taxation paid |
(1,411) |
(1,375) |
(1,919) |
|
|
|
---- |
---- |
---- |
|
|
Net cash inflow from operating activities |
5,067 |
4,777 |
6,161 |
|
|
|
---- |
---- |
---- |
|
|
Cash flow from investing activities |
|
|
|
|
|
Purchase of property, plant and equipment |
(938) |
(1,042) |
(1,516) |
|
|
Proceeds from sale of property, plant and equipment |
14 |
23 |
35 |
|
|
Purchase of intangible assets |
(346) |
(491) |
(627) |
|
|
Proceeds from sale of intangible assets |
170 |
7 |
9 |
|
|
Purchase of equity investments |
(53) |
(158) |
(186) |
|
|
Proceeds from sale of equity investments |
32 |
45 |
45 |
|
|
Purchase of businesses, net of cash acquired |
(324) |
(233) |
(1,027) |
|
|
Investment in associates and joint ventures |
(7) |
(1) |
(1) |
|
|
Interest received |
269 |
208 |
247 |
|
|
Dividends from associates and joint ventures |
9 |
11 |
12 |
|
|
|
---- |
---- |
---- |
|
|
Net cash outflow from investing activities |
(1,174) |
(1,631) |
(3,009) |
|
|
|
---- |
---- |
---- |
|
|
Cash flow from financing activities |
|
|
|
|
|
Decrease/(increase) in liquid investments |
802 |
(19) |
(39) |
|
|
Proceeds from own shares for employee share options |
- |
104 |
116 |
|
|
Shares acquired by ESOP Trusts |
(9) |
- |
(26) |
|
|
Issue of share capital |
58 |
368 |
417 |
|
|
Purchase of own shares for cancellation |
(3,324) |
- |
(213) |
|
|
Purchase of Treasury shares |
- |
(2,330) |
(3,538) |
|
|
Increase in long-term loans |
5,248 |
983 |
3,483 |
|
|
Repayment of long-term loans |
- |
(207) |
(207) |
|
|
Net (repayment of)/increase in short-term loans |
(2,648) |
451 |
1,632 |
|
|
Net repayment of obligations under finance leases |
(34) |
(29) |
(39) |
|
|
Interest paid |
(324) |
(279) |
(378) |
|
|
Dividends paid to shareholders |
(2,250) |
(2,126) |
(2,793) |
|
|
Dividends paid to minority interests |
(69) |
(69) |
(77) |
|
|
Other financing cash flows |
(32) |
(77) |
(79) |
|
|
|
---- |
---- |
---- |
|
|
Net cash outflow from financing activities |
(2,582) |
(3,230) |
(1,741) |
|
|
|
---- |
---- |
---- |
|
|
|
|
|
|
|
|
Increase/(decrease) in cash and bank overdrafts in the period |
1,311 |
(84) |
1,411 |
|
|
|
|
|
|
|
|
Exchange adjustments |
354 |
(1) |
48 |
|
|
Cash and bank overdrafts at beginning of period |
3,221 |
1,762 |
1,762 |
|
|
|
---- |
---- |
---- |
|
|
Cash and bank overdrafts at end of period |
4,886 |
1,677 |
3,221 |
|
|
|
---- |
---- |
---- |
|
|
|
|
|
|
|
|
Cash and bank overdrafts at end of period comprise: |
|
|
|
|
|
|
Cash and cash equivalents |
5,148 |
2,050 |
3,379 |
|
|
Overdrafts |
(262) |
(373) |
(158) |
|
|
---- |
---- |
---- |
|
|
|
4,886 |
1,677 |
3,221 |
|
|
|
---- |
---- |
---- |
|
|
Statement of recognised income and expense |
|
|
9 months 2008 |
9 months 2007 |
|
|
---- |
---- |
|
Exchange movements on overseas net assets |
362 |
89 |
|
Tax on exchange movements |
(5) |
(4) |
|
Fair value movements on available-for-sale investments |
(48) |
(59) |
|
Deferred tax on fair value movements on available-for-sale investments |
11 |
7 |
|
Exchange movements on goodwill in reserves |
(41) |
(1) |
|
Actuarial (losses)/gains on defined benefit plans |
(960) |
1,172 |
|
Deferred tax on actuarial movements in defined benefit plans |
296 |
(352) |
|
Fair value movements on cash flow hedges |
1 |
(7) |
|
Deferred tax on fair value movements on cash flow hedges |
(1) |
3 |
|
|
---- |
---- |
|
Net (losses)/gains recognised directly in equity |
(385) |
848 |
|
|
|
|
|
Profit for the period |
3,695 |
4,234 |
|
|
---- |
---- |
|
Total recognised income and expense for the period |
3,310 |
5,082 |
|
|
---- |
---- |
|
|
|
|
|
Total recognised income and expense for the period attributable to: |
|
|
|
Shareholders |
3,237 |
4,992 |
|
Minority interests |
73 |
90 |
|
|
---- |
---- |
|
|
3,310 |
5,082 |
|
|
---- |
---- |
|
Independent review report to GlaxoSmithKline plc Introduction We have been engaged by the company to review the condensed financial information in the results announcement for the third quarter 2008 (the 'Interim Management Statement') for the three and nine months ended 30th September 2008 which comprises the income statements, balance sheet, statement of recognised income and expense, cash flow statement and related notes (excluding the pharmaceuticals and vaccines pipeline table). We have read the other information contained in the interim management statement and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements. Directors' responsibilities The Interim Management Statement is the responsibility of, and has been approved by, the Directors. The Directors are responsible for preparing the Interim Management Statement in accordance with the Disclosure and Transparency Rules of the United Kingdom's Financial Services Authority. The condensed financial information in the Interim Management Statement for the three months and nine months ended 30th September 2008 has been prepared in accordance with the basis of preparation set out in the Accounting Presentation and Policies note and the Disclosure and Transparency Rules of the United Kingdom's Financial Services Authority. Our responsibility Our responsibility is to express to the company a conclusion on the condensed financial information in the Interim Management Statement based on our review. This report, including the conclusion, has been prepared for and only for the Company for the purpose of the Disclosure and Transparency Rules of the Financial Services Authority and for no other purpose. We do not, in producing this report, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing. Scope of review We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Auditing Practices Board for use in the United Kingdom. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Conclusion Based on our review, nothing has come to our attention that causes us to believe that the condensed financial information in the Interim Management Statement for the three months and nine months ended 30th September 2008 is not prepared, in all material respects, in accordance with the basis of preparation set out in the Accounting Presentation and Policies note and the Disclosure and Transparency Rules of the United Kingdom's Financial Services Authority. PricewaterhouseCoopers LLP Chartered Accountants London 22nd October 2008 |
|
Notes: |
|
|
(a) |
The maintenance and integrity of the GlaxoSmithKline plc website is the responsibility of the directors; the work carried out by the auditors does not involve consideration of these matters and, accordingly, the auditors accept no responsibility for any changes that may have occurred to the interim report since it was initially presented on the website. |
|
|
|
|
(b) |
Legislation in the United Kingdom governing the preparation and dissemination of financial information may differ from legislation in other jurisdictions. |
This information is provided by RNS
Latest directors dealings
- 6 minutes ago Savannah Energy
- 25 minutes ago Carclo
- 41 minutes ago Schroder Japan Growth Fund
- 1 hour ago Schroder Income Growth Fund
- 1 hour ago CVC Income & Growth Limited NPV GBP